Oncternal Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 44.17 million compared to USD 31.33 million a year ago. Basic loss per share from continuing operations was USD 16.8 compared to USD 12.8 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.21 USD | +1.21% | +6.35% | -14.12% |
05-09 | Transcript : Oncternal Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
05-09 | Oncternal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.12% | 26.93M | |
+67.53% | 62.86B | |
-0.77% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+13.30% | 26.46B | |
-22.79% | 18.9B | |
+4.70% | 12.67B | |
+24.10% | 12.27B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- ONCT Stock
- News Oncternal Therapeutics, Inc.
- Oncternal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022